CRNX vs. IONS, AVDL, BCYC, AGLE, VTRS, UTHR, RDY, SRPT, CTLT, and ELAN
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Ionis Pharmaceuticals (IONS), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Aeglea BioTherapeutics (AGLE), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Ionis Pharmaceuticals has a net margin of -49.49% compared to Ionis Pharmaceuticals' net margin of -4,223.27%. Ionis Pharmaceuticals' return on equity of -42.50% beat Crinetics Pharmaceuticals' return on equity.
Ionis Pharmaceuticals received 534 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 67.76% of users gave Crinetics Pharmaceuticals an outperform vote while only 60.20% of users gave Ionis Pharmaceuticals an outperform vote.
Ionis Pharmaceuticals currently has a consensus price target of $59.54, indicating a potential upside of 49.63%. Crinetics Pharmaceuticals has a consensus price target of $62.50, indicating a potential upside of 38.86%. Given Crinetics Pharmaceuticals' higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 9 mentions for Crinetics Pharmaceuticals and 4 mentions for Ionis Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.18 beat Ionis Pharmaceuticals' score of 0.65 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
Ionis Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Crinetics Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
